Compare Msci Inc (MSCI) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs Tilray Brands Inc — how do they compare? Msci Inc trades at $563.73 (market cap $40.38B), while Tilray Brands Inc trades at $3.44 (market cap $530.54M). The key difference: Msci Inc is far larger — about 76.1× Tilray Brands Inc's market cap, and Msci Inc pays a 1.48% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and Tilray Brands Inc for 31 Days on average.
| MSCI | TLRY | |
|---|---|---|
Market Cap | $40.38B | $530.54M |
Volume | 414,140 | 9,099,075 |
Sector | Financials | Health |
52-Week High | $643.83 | $21.00 |
52-Week Low | $511.84 | $3.57 |
Typical Hold Time | 82 Days | 31 Days |
Enterprise Value | $46.54B | $684.46M |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $565.05, up 1.74% on the day, with a neutral technical signal and key resistance near $567. The company reported Q2 2026 earnings of $4.94 per share, slightly missing estimates, but maintains strong fundamentals with 40.73% net income margin and revenue growth to $3.13 billion in 2025. Recent news includes the completion of the First Street acquisition and upcoming Q3 2026 earnings call.
The outlook is supported by high analyst bullishness (74% buy ratings) and a consensus price target of $701.71, implying significant upside. Risks include high valuation multiples (P/E 30.37) and substantial long-term debt of $4.51 billion. Earnings growth and execution on strategic acquisitions are critical for sustaining momentum.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
